International WELL Building Institute Launches WELL Health-Safety Rating for all Building and Facility Types
The International WELL Building Institute (IWBI) announced today the launch of the WELL Health-Safety Rating for all building and facility types, an evidence-based, third-party verified rating focusing on operational policies, maintenance protocols and design strategies to address a post COVID-19 environment. The WELL Health-Safety Rating is one of the earliest outcomes of IWBI’s Task Force on COVID-19, a group of nearly 600 public health experts, virologists, government officials, academics, business leaders, architects, designers, building scientists and real estate professionals, which was established in late March to help guide IWBI’s response to the pandemic.
The WELL Health-Safety Rating provides a centralized source and governing body to validate efforts made by owners and operators. It leverages insights drawn from the IWBI COVID-19 Task Force, in addition to guidance on the spread of COVID-19 and other respiratory infections developed by the Centers for Disease Control and Prevention (CDC), the World Health Organization (WHO), the Department of Health and Human Services pursuant to the Occupational Safety and Health Act (OSHA), the National Institutes of Health (NIH), and leading academic and research institutions, as well as core principles already established by IWBI’s WELL Building Standard. Participation in the program requires submission of policies, protocols and strategies for third-party document review and annual verification.
“The WELL Health-Safety Rating is a sign of confidence that measures have been enacted to help support the health and safety of people entering spaces of all kinds, and that those measures have been mapped to scientific evidence and verified through a third-party review process,” said Rick Fedrizzi, chairman & CEO of IWBI. “By drawing on the proven strategies in WELL, we’re working from the best science available and that’s more important than it’s ever been.”
The WELL Health-Safety Rating will accept registrations in June from all types of buildings and facility typologies, including offices, restaurants, hotels, retail establishments, manufacturing plants, warehouses, sports stadiums, arenas, theaters and other entertainment venues, schools, multi-family housing, and many others. Current WELL-registered projects and WELL Portfolio participants can earn the WELL Health-Safety Rating as part of their already established certification efforts.
“Our buildings and the people who tend them are our first line of defense for keeping us safe and healthy,” said Rachel Gutter, president of IWBI, “and the current pandemic has confirmed that health is a material economic consideration of the first order. These two simple truths stand at the nexus of our work to date and will, along with the hard evidence that is mounting, inform all our decisions about the critical need for better buildings, more vibrant communities and stronger organizations going forward.”
The WELL Health-Safety Rating is the first of many anticipated outcomes informed by the work of the IWBI COVID-19 Task Force that will be introduced in the coming months. Members of the Task Force include 17th Surgeon General of the United States Dr. Richard Carmona, former Robert Wood Johnson Foundation President and CEO Dr. Risa Lavizzo-Mourey, UCLA’s Dr. Jonathan Fielding, Harvard School of Public Health’s Joseph Allen, and environmental scientist Allen Hershkowitz Ph.D., among others.
“The Task Force has received overwhelming support and input from all over the world,” said Dr. Richard Carmona, 17th Surgeon General of the United States. “People are learning that buildings themselves can be powerful vehicles for protecting and improving public health. All of us individually have a responsibility to the collective whole to use every tool, including our buildings and our sense of community, to keep ourselves and those we care about safe.”
“The impacts of the virus have been many, but not the least is the anxiety of uncertainty about where people feel safe,” said Despina Katsikakis, Head of Occupier Business Performance at Cushman Wakefield and member of IWBI’s COVID-19 Task Force. “Achieving this new WELL Health-Safety Rating is a great way to increase confidence that evidence-based steps to do the right thing have been taken to keep health front and center as the economy reopens.”
Recently, IWBI released an interim Strategies from the WELL Building Standard to Support in the Fight Against COVID-19, another key outcome of the Task Force. Grounded in the foundation of WELL, these evidence-based strategies provide an actionable framework for organizations and communities as they advance a safer and healthier future. IWBI is expanding these strategies into Guidelines for Preparedness and Prevention, Resilience and Recovery in relation to COVID-19 and other respiratory infections. The Guidelines will provide insight into how the current strategies have evolved, as well as indicate areas where further work is required.
Since its inception, IWBI has been driving forward the convergence of building science and health science. Registrations under the WELL Building Standard, the premier standard for healthy real estate, have already surpassed 550 million square feet across 62 countries. The WELL Building movement has been further amplified by over 11,000 WELL Accredited Professionals (APs) and registrants across the globe.
Gutter noted that upon achieving the designation, IWBI will issue the project a WELL Health-Safety Rating seal. Register interest in the WELL Health-Safety Rating here.
About the International WELL Building Institute
The International WELL Building Institute (IWBI) is leading the global movement to transform our buildings, communities and organizations in ways that help people thrive. The WELL v2 pilot is the latest version of its popular WELL Building Standard (WELL), and the WELL Community Standard pilot is a district scale rating system that sets a new global benchmark for healthy communities. WELL is focused exclusively on the ways that buildings and communities, and everything in them, can improve our comfort, drive better choices, and generally enhance, not compromise, our health and wellness. IWBI mobilizes the wellness community through management of the WELL AP credential, the pursuit of applicable research, the development of educational resources, and advocacy for policies that promote health and wellness for everyone, everywhere. For more information about IWBI and WELL, visit us here.
International WELL Building Institute, IWBI, the WELL Building Standard, WELL v2, WELL Certified, WELL AP, WELL, WELL Portfolio, The WELL Conference, the WELL Community Standard, WELL Workforce, WELL Health-Safety Rating and others, and their related logos are trademarks or certification marks of International WELL Building Institute pbc in the United States and other countries.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200608005495/en/
Contact information
Press:
Judith Webb
media@wellcertified.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CCM Biosciences Announces Presentation of Data on its First-In-Class AML Drug Program at ASCO 202520.5.2025 23:30:00 EEST | Press release
CCM Biosciences, a diversified pharmaceutical discovery and development company, today announced the upcoming presentation of its next-generation FLT3 inhibitor drug program for acute myeloid leukemia (AML) at the 2025 Annual Conference of the American Society of Clinical Oncology (ASCO), taking place May 30 to June 3 in Chicago. Acute Myeloid Leukemia (AML) is the most severe form of leukemia with few treatment options, and a malignancy frequently driven by mutations in the FMS-like tyrosine kinase 3 (FLT3) gene. The FLT3 internal tandem duplication (ITD) and tyrosine kinase domain (TKD) mutations, particularly D835 and F691, appear in approximately 30% of AML patients, often leading to poor prognosis and resistance to existing therapies. Gilteritinib (Xospata®; Astellas Pharma, peak annual sales projection: $1.5 billion) and Quizartinib (Vanflyta®; Daiichi Sankyo) are two FDA-approved FLT3 inhibitors, with the former approved only for relapsed/refractory AML and the latter approved o
IonQ Partners with Sweden’s Einride to Develop Quantum Supply Chain and Quantum-Enhanced Logistics for Autonomous Driving Solutions20.5.2025 23:05:00 EEST | Press release
IonQ (NYSE: IONQ), a leading commercial quantum computing and networking company, today announced an investment partnership with Einride, a leading global freight mobility company that provides digital, electric, and autonomous technology to explore how quantum computing can drive the next generation of fleet optimization and logistics. Together, IonQ and Einride will develop quantum applications that address large-scale routing and scheduling problems that have traditionally challenged classical computing. By combining IonQ’s advanced quantum systems with Einride’s expertise in autonomous fleet logistics, the two companies will work to unlock new levels of efficiency, reliability, and sustainability for the global freight industry. “Einride shares our belief that quantum computing will fundamentally reshape and improve how large industries such as transportation and logistics operate,” said Niccolo de Masi, CEO of IonQ. “This partnership is aimed at creating a powerful platform with u
CCM Biosciences Announces Presentation of Data on its First-In-Class NSCLC Drug Program at ASCO 202520.5.2025 22:26:00 EEST | Press release
CCM Biosciences, a diversified pharmaceutical discovery and development company, today announced the upcoming presentation of its 4th-generation EGFR inhibitor drug program for non-small cell lung cancer (NSCLC) at the 2025 Annual Conference of the American Society of Clinical Oncology (ASCO), taking place May 30 to June 3 in Chicago. NSCLC, which accounts for 80% of lung cancer, is the most common cause of cancer death worldwide. Epidermal growth factor receptor (EGFR)-activating mutations (Del19 or L858R) are major oncogenic drivers of NSCLC. EGFR-positive NSCLC accounts for approximately 30% of all diagnosed cases of NSCLC (a similar market size to PD-L1-positive NSCLC, which is addressed by the world’s top-selling drug, Keytruda®). The current standard of care for EGFR-positive NSCLC is comprised of 3rd-generation inhibitors, most notably Osimertinib (Tagrisso®), whose annual sales exceed $6 billion. Most patients treated by tyrosine kinase inhibitors (TKIs) will eventually develop
NielsenIQ's Chief Technology Officer Mohit Kapoor Named Executive of the Year at Global Tech & AI Awards for Leading NIQ’s AI-Driven Tech Transformation20.5.2025 22:24:00 EEST | Press release
NielsenIQ (NIQ) is proud to announce that Mohit Kapoor, Chief Technology Officer, was named Executive of the Year at the inaugural Global Tech & AI Awards. This honor recognizes Mohit's exceptional leadership and visionary contributions to the tech industry, particularly in the realm of AI-powered consumer intelligence. "I am deeply honored to receive the Executive of the Year award at the Global Tech & AI Awards. This recognition is a testament to the incredible work and dedication of the entire NielsenIQ team,” said Mohit Kapoor, Chief Technology Officer, NIQ. “Together, we have redefined consumer and retail intelligence, leveraging AI to deliver unparalleled insights and drive meaningful change in the industry." Under Mohit's leadership, NIQ has adopted an AI-powered approach to its ambitious digital transformation which included a $400 million technology investment and the migration of its global client base onto Discover– a unified, cloud-based platform that seamlessly integrates
Strategic Partnership Between the Government of Morocco and TAQA Morocco, Nareva, ONEE and the Mohammed VI Investment Fund to Develop Key Power and Water Infrastructures in the Kingdom of Morocco20.5.2025 22:08:00 EEST | Press release
As part of the implementation of the commitments made in the joint declaration between His Majesty King Mohammed VI, may God Assist Him, and His Highness Sheikh Mohamed bin Zayed Al Nahyan, TAQA Morocco, in partnership with Nareva and the Mohammed VI Fund for Investment, has signed three memorandums of understanding and related development agreements with the Government of Morocco and ONEE. These agreements cover the development of structuring projects in the power, water and renewable energy sectors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250520313620/en/ Strategic Partnership Between the Government of Morocco and TAQA Morocco, Nareva, ONEE and the Mohammed VI Investment Fund to Develop Key Power and Water Infrastructures in the Kingdom of Morocco (Photo: AETOSWire) The program aims to strengthen the Kingdom's water and energy sovereignty through the development of flexible natural gas-based power generation capacit
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom